Tags

Type your tag names separated by a space and hit enter

What happened to WHI: menopausal hormonal therapy in 2012.
Clin Obstet Gynecol. 2012 Sep; 55(3):706-12.CO

Abstract

Menopause is characterized by amenorrhea for 1 year due to the cessation of ovarian function. The hormonal treatment of menopause has significantly altered since the publication of initial results from the Women's Health Initiative continuous, combined, conjugated equine estrogen with medroxyprogesterone acetate study arm in 2002. Current studies suggest that treatment should be individualized and that the lowest dose of estrogen providing relief should be used for the shortest period of time in menopausal women who experience vasomotor symptoms or urogenital atrophy. Future studies into different delivery mechanisms such as transdermal applications and different agents, such as tibolone and raloxifene, will help refine the treatment of menopause.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Sanford School of Medicine of The University of South Dakota, Health Science Center, Sioux Falls, SD, USA. kahansen@usd.eduNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22828102

Citation

Hansen, Keith A., and Kathleen M. Eyster. "What Happened to WHI: Menopausal Hormonal Therapy in 2012." Clinical Obstetrics and Gynecology, vol. 55, no. 3, 2012, pp. 706-12.
Hansen KA, Eyster KM. What happened to WHI: menopausal hormonal therapy in 2012. Clin Obstet Gynecol. 2012;55(3):706-12.
Hansen, K. A., & Eyster, K. M. (2012). What happened to WHI: menopausal hormonal therapy in 2012. Clinical Obstetrics and Gynecology, 55(3), 706-12. https://doi.org/10.1097/GRF.0b013e31825cab41
Hansen KA, Eyster KM. What Happened to WHI: Menopausal Hormonal Therapy in 2012. Clin Obstet Gynecol. 2012;55(3):706-12. PubMed PMID: 22828102.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - What happened to WHI: menopausal hormonal therapy in 2012. AU - Hansen,Keith A, AU - Eyster,Kathleen M, PY - 2012/7/26/entrez PY - 2012/7/26/pubmed PY - 2012/12/28/medline SP - 706 EP - 12 JF - Clinical obstetrics and gynecology JO - Clin Obstet Gynecol VL - 55 IS - 3 N2 - Menopause is characterized by amenorrhea for 1 year due to the cessation of ovarian function. The hormonal treatment of menopause has significantly altered since the publication of initial results from the Women's Health Initiative continuous, combined, conjugated equine estrogen with medroxyprogesterone acetate study arm in 2002. Current studies suggest that treatment should be individualized and that the lowest dose of estrogen providing relief should be used for the shortest period of time in menopausal women who experience vasomotor symptoms or urogenital atrophy. Future studies into different delivery mechanisms such as transdermal applications and different agents, such as tibolone and raloxifene, will help refine the treatment of menopause. SN - 1532-5520 UR - https://www.unboundmedicine.com/medline/citation/22828102/What_happened_to_WHI:_menopausal_hormonal_therapy_in_2012_ L2 - https://dx.doi.org/10.1097/GRF.0b013e31825cab41 DB - PRIME DP - Unbound Medicine ER -